Table.
Patient Demographics, Usage of Hydroxychloroquine, and Abnormalities in Structural Imaging and Functional Testing
| Risk Factors for Toxicity | Abnormalitiesa | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID | Sex | Age (y) | HCQ Indication | Daily Dose (mg) | Daily Dose/RBW (mg/kg) | Duration (y) | Total Dose (g) | Daily Dose > 5 mg/kg | Duration > 10 y | Total dose > 1000 g | SW-AF | NIR-AF | SD-OCT |
| 1 | F | 72 | Lyme | 400 | 6.8 | 1 | 146 | X | |||||
| 2 | F | 65 | SLE | 400 | 5.9 | 15 | 2190 | X | X | X | |||
| 3 | F | 57 | SLE | 400 | 5.5 | 20 | 2920 | X | X | X | X | ||
| 4 | F | 78 | RA | 400 | 5.4 | 10 | 1460 | X | X | X | X | X | X |
| 5 | F | 53 | SLE | 400 | 4.4 | 13 | 1898 | X | X | ||||
| 6 | F | 33 | Sjögren's syndrome | 300 | 5.5 | 2 | 219 | X | |||||
| 7 | M | 22 | SLE | 400 | 4.8 | 7 | 1022 | X | |||||
| 8 | F | 70 | Sjögren's syndrome | 400 (200b) | 7.4 (3.7b) | 10 (10) | 2190 | X | X | X | X | ||
| 9 | F | 10 | Sjögren's syndrome | 200 | 7.0 | 2 | 146 | X | |||||
| 10 | F | 75 | RA | 500 | 7.3 | 12 | 2190 | X | X | X | X | ||
| 11 | F | 42 | MCTD | 300 | 4.41 | 5 | 548 | ||||||
| 12 | F | 57 | SLE | 400 | 4.8 | 3 | 438 | ||||||
| 13 | F | 23 | SLE | 400 | 3.9 | 1 | 146 | ||||||
| 14 | F | 16 | Lyme | 200 | 3.7 | 0.5 | 37 | ||||||
| 15 | F | 48 | RA | 400 | 5.9 | 9 | 1314 | X | X | ||||
| 16 | F | 69 | Sjögren's syndrome | 400 | 5.3 | 8.5 | 1241 | X | X | ||||
| 17 | F | 53 | SLE | 100 | 1.5 | 7 | 256 | ||||||
| 18 | F | 72 | RA | 400 (200b) | 6.5 (3.3b) | 16 (1) | 2409 | X | X | X | X | ||
| 19 | F | 9 | Polymyositis | 100 (200b) | 3.3 (6.7b) | 2.67 (0.33) | 122 | X | |||||
| 20 | M | 51 | Psoriatic arthritis | 400 | 5.8 | 9 | 1314 | X | X | X | |||
| 21 | F | 55 | RA | 200 | 2.9 | 0.2 | 15 | ||||||
| 22 | F | 18 | RA | 200 | 4.2 | 5 | 365 | X | |||||
| 23 | F | 50 | SLE | 400 | 7.2 | 10 | 1460 | X | X | X | X | X | X |
| 24 | F | 39 | SLE | 400 | 3.9 | 15 | 2190 | X | X | ||||
| 25 | F | 71 | RA | 400 (200b) | 6.8 (3.4b) | 9 (4) | 1606 | X | X | X | X | ||
| 26 | F | 35 | SLE | 400 | 6.8 | 8 | 1168 | X | X | ||||
| 27 | F | 49 | SLE | 400 | 4.4 | 5 | 730 | X | X | X | |||
| 28 | F | 45 | RA | 300 | 5.6 | 2 | 219 | X | |||||
| 29 | F | 58 | Behçet's syndrome | 200 | 4.2 | 7 | 511 | ||||||
| 30 | F | 66 | RA | 400 | 6.4 | 14.5 | 2117 | X | X | X | X | ||
| 31 | F | 20 | SLE | 200 | 4.0 | 1 | 73 | ||||||
| 32 | F | 52 | SLE | 400 | 8.9 | 10 | 1460 | X | X | X | X | X | X |
| 33 | F | 64 | SLE | 400 | 5.4 | 0.08 | 12 | X | |||||
| 34 | M | 86 | RA | 400 | 6.3 | 1 | 146 | X | |||||
| 35 | F | 80 | SLE | 200 | 1.9 | 20 | 1460 | X | X | ||||
| 36 | F | 68 | SLE | 300 | 4.9 | 3 | 329 | ||||||
| 37 | F | 72 | RA | 100 | 1.4 | 26 | 949 | X | |||||
| 38 | F | 68 | RA | 450 | 6.5 | 10 | 1643 | X | X | X | |||
| 39 | F | 67 | RA | 400 | 6.5 | 8 | 1168 | X | X | X | |||
| 40 | F | 74 | RA | 200 | 3.2 | 13 | 949 | X | |||||
| 41 | F | 43 | RA | 400 | 5.8 | 2 | 292 | X | |||||
| 42 | F | 23 | SLE | 400 | 7.9 | 2 | 292 | X | |||||
| 43 | F | 50 | RA | 400 | 4.6 | 7 | 1022 | X | |||||
| 44 | F | 34 | SLE | 200 | 3.7 | 12 | 876 | X | |||||
Given that all patients presented with bilateral abnormalities, we present this information in a per-patient manner. MCTD, mixed connective tissue disorder; RA, rheumatoid arthritis; RBW, real body weight.
a
Image analyses were performed per eye.
b
Denotes the current dose of HCQ that the patient was taking.